Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: A phase 2 trial
Patrick A. Burch, Gary A. Croghan, Dennis A. Gastineau, Lori A. Jones, Judith S. Kaur, Jelle W. Kylstra, Ronald L. Richardson, Frank H. Valone, Stanimir Vuk-PavlovićVolume:
60
Year:
2004
Language:
english
Pages:
8
DOI:
10.1002/pros.20040
File:
PDF, 150 KB
english, 2004